Active treatments are a rational approach for hepatocellular carcinoma in elderly patients

Table 1 Basic characteristics

Age (yr)	67.0 (60.0-73.0)1
Gender (male/female)	647/271
HBsAg (-/+/ND)	582/196/140
anti-HCV (-/+/ND)	278/534/106
AIH/PBC/alcohol/NASH/BCS	10/6/85/16/2
Child-Pugh (A/B/C/ND)	704/172/36/6
Size (mm)	28.0 (19.0-45.0)1
Stage (I/II/III/IV)2	163/306/287/162
Therapy (Loco/IVR/Cx/others/BSC)	459/332/78/11/38

¹Median and interquartile range;

²General rules for the clinical and pathological study of primary liver cancer from Liver Cancer Study Group of Japan. ND: Not determined; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; NASH: Nonalcoholic steatohepatitis; BCS: Budd-Chiari syndrome; Loco: Logo-regional treatments, including resection, radiofrequency ablation, microwave coagulation and percutaneous ethanol injection; IVR: Interventional radiology including transcatheter arterial chemoembolization, and transarterial oily chemoembolization; Cx: Chemotherapy including hepatic arterial infusion chemotherapy, systemic chemotherapy and molecular targeting therapy; Others: Other therapies including stereotactic body radiation, proton beam and liver transplantation; BSC: Best supportive care; HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus.